期刊文献+

Toll样受体2在缺血性脑损伤中的作用机制研究进展 被引量:3

Recent advance in mechanism of Toll-like receptor 2 in cerebral ischemic injury
原文传递
导出
摘要 缺血性脑损伤的发生机制极其复杂,大量研究表明炎症反应是其主要机制之一。炎性瀑布反应触发并加剧了缺血性脑损伤的发展,其中炎性受体发挥了重要作用。实验研究表明Toll样受体2(TLR2)在缺血性脑损伤的发生、发展和继发性脑损伤中可能起重要作用。髓样分化因子88(MyD88)是TLR2信号传导通路中关键的衔接蛋白,能够启动下游炎性因子的传导,而Mvd88主要参与对核转录因子-κB(NF-κB)DNA结合活性的调控。本文就TLR2介导的MyD88信号传导通路在缺血性脑损伤中的可能作用机制进行综述,希望能够以TLR2和MyD88作为信号传导通路中的核心环节,成为药物靶向治疗的研究对象,为减轻缺血性脑损伤提供新的对策。 The mechanism of cerebral ischemic injury is very complex. A lot of studies have shown that inflammatory reaction is one of the main mechanisms of cerebral ischemic injury, and the inflammatory response of the waterfall is more important. Experimental studies show that Toll like receptor 2 (TLR2) may play an important role in the initiation and development of cerebral ischemia, and may lead to the secondary brain injury. Myeloid differentiation factor 88 (MyD88) is the key of the TLR2 signal transduction pathway, which can activate the downstream inflammatory factors. And myd88 is mainly involved in the regulation ofNF-KB DNA binding activity. The role of MyD88 signaling pathway mediated by TLR2 is reviewed in cerebral ischemic injury in this paper. MyD88 is the key link in the signal transduction pathway, which can be used as the research object of drug targeting therapy.
作者 位云 孟强
出处 《中华神经医学杂志》 CAS CSCD 北大核心 2016年第9期955-960,共6页 Chinese Journal of Neuromedicine
基金 国家自然科学基金(81460188),云南省应用基础研究(昆医联合专项)(2013FB201),云南省中青年学术和技术带头人后备人才(2012HB028),云南省卫生系统学科带头人(D-201235),王陇德院士工作站
关键词 缺血性脑损伤 炎症反应 TOLL样受体2 髓样分化因子88 Ischemic brain injury Inflammation Toll-like recepter 2 Myeloid differentiation primary response gene (88)
  • 相关文献

参考文献6

二级参考文献41

  • 1陈辉星,尹路,彭承宏.Toll-样受体在器官移植免疫中的作用[J].国际外科学杂志,2006,33(1):41-43. 被引量:5
  • 2Suzhen Zhang,Xuhui Zhao,Dechun Zhang.Cellular and Molecular Immunopathogenesis of Ulcerative Colitis[J].Cellular & Molecular Immunology,2006,3(1):35-40. 被引量:25
  • 3陈国俊,秦震.大鼠插线法大脑中动脉缺血-再灌流模型的方法学与改进[J].临床神经科学,1996,4(3):150-152. 被引量:4
  • 4Tanaka K.Expression of Toll-like receptors in the intestinal mucosa of patients with inflammatory bowel disease[J].Expert Rev Gastroenterol Hepatol,2008,2(2):193-196.
  • 5Szebeni B,Veres G,Dezsfi A,et al.Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease[J].Clin Exp Immunol,2007,151(1):34-41.
  • 6Fort MM,Mozaffarian A,Stover AG,et al.A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease[J].J Immunol,2005,174(10):6 416-6 423.
  • 7Hanauer SB.Inflammatory bowel disease:epidemiology,pathogenesis and therapeutic opportunities[J].Inflamm Bowel Dis,2006,12(S1):3-9.
  • 8Liu Y,Zhang ZJ,Wang L,et al.TLR4 monoclonal antibody blockade suppresses dextran sulfate sodium-induced colitis in mice[J].J Gastroen Hepatol,2010,25(1):209-214.
  • 9Alex P,Zachos NC,Nguyen T,et al.Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis[J].Inflamm Bowel Dis,2009,15(3):341-352.
  • 10Rovedatti L,Kudo T,Biancheri P,et al.Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease[J].Gut,2009,58(12):1 629-1 636.

共引文献50

同被引文献15

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部